MLICM
CDAK

Metropolitan Life Insurance Company (MetLife)’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,152
Closed -$84.1K – 2855
2021
Q3 		$84.1K Buy
+5,152
New +$92.2K ﹤0.01% 2623

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $863M AUM 30.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.44B AUM 23.16% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CDAK Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q4 2021, closing a stake of 5,152 shares — an estimated $84.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CDAK in Q3 2021 and held it in 1 quarter. The position peaked at $84.1K in Q3 2021. 51 funds tracked by Wall St. Rank hold CDAK as of Q4 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 5,152 Codiak BioSciences, Inc. Common Stock shares in Q4 2021, an estimated $84.1K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Codiak BioSciences, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Codiak BioSciences, Inc. Common Stock position peaked at $84.1K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.